IS2675B - P38-hindrar og aðferðir til notkunar þeirra - Google Patents

P38-hindrar og aðferðir til notkunar þeirra

Info

Publication number
IS2675B
IS2675B IS8037A IS8037A IS2675B IS 2675 B IS2675 B IS 2675B IS 8037 A IS8037 A IS 8037A IS 8037 A IS8037 A IS 8037A IS 2675 B IS2675 B IS 2675B
Authority
IS
Iceland
Prior art keywords
inhibitors
methods
Prior art date
Application number
IS8037A
Other languages
English (en)
Other versions
IS8037A (is
Inventor
Mark Munson
David A Mareska
Youngboo Kim
Robert Groneberg
James Rizzi
Martha Rodriguez
Ganghyeok Kim
Guy Vigers
Chang Rao
Devan Balachari
Darren Harvey
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/378,164 external-priority patent/US7135575B2/en
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of IS8037A publication Critical patent/IS8037A/is
Publication of IS2675B publication Critical patent/IS2675B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
IS8037A 2003-03-03 2005-09-21 P38-hindrar og aðferðir til notkunar þeirra IS2675B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/378,164 US7135575B2 (en) 2003-03-03 2003-03-03 P38 inhibitors and methods of use thereof
US10/688,849 US20040180896A1 (en) 2003-03-03 2003-10-15 P38 inhibitors and methods of use thereof
PCT/US2004/005693 WO2004078116A2 (en) 2003-03-03 2004-02-25 P38 inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
IS8037A IS8037A (is) 2005-09-21
IS2675B true IS2675B (is) 2010-09-15

Family

ID=32965317

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8037A IS2675B (is) 2003-03-03 2005-09-21 P38-hindrar og aðferðir til notkunar þeirra

Country Status (12)

Country Link
US (1) US7521447B2 (is)
EP (1) EP1606283B1 (is)
JP (1) JP4617299B2 (is)
KR (1) KR101099281B1 (is)
AU (1) AU2004218463B2 (is)
CA (1) CA2517517C (is)
IS (1) IS2675B (is)
MX (1) MXPA05009459A (is)
NO (1) NO328913B1 (is)
PL (1) PL214032B1 (is)
RU (1) RU2357957C2 (is)
WO (1) WO2004078116A2 (is)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1562905A2 (en) * 2002-10-24 2005-08-17 MERCK PATENT GmbH Methylene urea derivatives as raf-kinase inhibitors
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1670787B1 (en) * 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
CA2558109A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
EP1778686B9 (en) 2004-08-12 2009-07-08 Pfizer Limited Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
RU2007114112A (ru) * 2004-11-02 2008-12-10 Пфайзер Инк. (US) Способ получения индазольных соединений
WO2006048744A1 (en) * 2004-11-02 2006-05-11 Pfizer Inc. Methods of preparing indazole compounds
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
EP1883404A4 (en) * 2005-05-11 2010-03-31 Array Biopharma Inc P38 INHIBITORS AND METHODS OF USE
MX2008002383A (es) * 2005-08-25 2008-03-18 Hoffmann La Roche Pirazol fusionado como inhibidores de proteinas cinasas activadas por mitogenos p38.
AU2006283940A1 (en) * 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
WO2007023111A2 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1931668A2 (en) * 2005-09-16 2008-06-18 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
DE602006021205D1 (de) 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
WO2007047397A2 (en) * 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
EP2514751A1 (en) * 2005-11-15 2012-10-24 Vertex Pharmaceuticals, Inc. Azaindazoles useful as inhibitor of kinases
JPWO2007063868A1 (ja) * 2005-11-29 2009-05-07 東レ株式会社 アリールメチレンウレア誘導体及びその用途
SI1981851T1 (sl) * 2006-01-31 2012-05-31 Array Biopharma Inc Kinazni inhibitorji in postopki za njihovo uporabo
CN101454313A (zh) * 2006-03-29 2009-06-10 阿雷生物药品公司 P38抑制剂及其使用方法
EP2695608B1 (en) * 2006-10-03 2016-11-23 Arbutus Biopharma Corporation Lipid containing formulations
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
JP5311673B2 (ja) * 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
WO2008076446A1 (en) * 2006-12-18 2008-06-26 Coleman Peter R Accelerated opiate dependence detoxification process
CN101558072A (zh) * 2006-12-19 2009-10-14 霍夫曼-拉罗奇有限公司 吡唑并[3,4-d]嘧啶p38map激酶抑制剂
ES2509820T3 (es) * 2006-12-20 2014-10-20 Nerviano Medical Sciences S.R.L. Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8202899B2 (en) * 2007-07-25 2012-06-19 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
BRPI0916774A2 (pt) * 2008-07-15 2018-02-20 Hoffmann La Roche derivados de indolila e indazolila substituídos e usos dos mesmos
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
WO2010067130A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US20110086837A1 (en) * 2009-10-12 2011-04-14 Genentech, Inc. Combinations of a pi3k inhibitor and a mek inhibitor
JP2013519685A (ja) 2010-02-11 2013-05-30 ヴァンダービルト ユニバーシティー ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法
US8901313B2 (en) 2011-03-16 2014-12-02 Genentech, Inc. 6,5-heterocyclic propargylic alcohol compounds and uses therefor
BR112014013177A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
US9278936B2 (en) * 2012-03-01 2016-03-08 Array Biopharma Inc. Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride
WO2014032755A2 (en) * 2012-08-29 2014-03-06 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
JP6300042B2 (ja) 2012-10-12 2018-03-28 エグゼリクシス， インコーポレイテッド 癌の処置に使用するための化合物の製造方法
EP2961744B1 (en) 2013-02-27 2017-06-28 Array Biopharma, Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
EP3842424B1 (en) 2013-03-15 2024-12-11 The Trustees of Columbia University in the City of New York Map kinase modulators and uses thereof in the tretament of tauopathies
PT3057934T (pt) * 2013-10-18 2019-06-28 Blanchette Rockefeller Neurosciences Inst Ésteres halogenados de ácidos gordos insaturados ciclopropanados para uso no tratamento de doenças neurodegenerativas
CN104974160B (zh) * 2014-04-08 2017-12-05 辰欣药业股份有限公司 2‑甲基吡唑并[1,5‑a]嘧啶‑6‑羧酸衍生物及其应用
WO2016114816A1 (en) * 2015-01-18 2016-07-21 Sri International MAP4K4 (HGK) Inhibitors
RU2675496C1 (ru) * 2017-03-31 2018-12-20 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения алкиловых эфиров гидроксибензойных кислот
CN108947879B (zh) * 2017-05-17 2022-06-28 中国科学院上海药物研究所 Prmt i型抑制剂及其制备方法和用途
JP2021501130A (ja) 2017-10-05 2021-01-14 フルクラム セラピューティクス，インコーポレイテッド ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
EP4051665A1 (en) 2019-10-28 2022-09-07 Teva Pharmaceuticals International GmbH Solid state forms of arry-797 and process for preparation thereof
US20210308117A1 (en) 2020-03-20 2021-10-07 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN113354558B (zh) * 2021-07-12 2022-03-11 无锡双启科技有限公司 一种2-氨基-5-氟苯腈的制备方法
CN115850179B (zh) * 2022-12-13 2025-03-25 北京科翔中升医药科技有限公司 一种氘代吲唑类mapk抑制剂药物及用途
WO2025056518A1 (en) * 2023-09-11 2025-03-20 Univerza V Ljubljani 5,6-DISUBSTITUTED ALKYL 1H AND 2H-INDAZOLES AS DUAL BUTYRYLCHOLINESTERASE AND p38α MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998060A (ja) * 1982-11-27 1984-06-06 Fujisawa Pharmaceut Co Ltd インダゾ−ル誘導体、その製造法および農薬
US4571255A (en) * 1983-12-29 1986-02-18 Ppg Industries, Inc. Subsituted phenoxybenzisoxazole herbicides
JPS6368568A (ja) * 1986-09-10 1988-03-28 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
IE910278A1 (en) * 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
CA2116863A1 (en) * 1992-07-03 1994-01-20 Sumio Yokota Condensed heterocyclic derivatives and herbicides
EP0684235A1 (en) * 1994-05-27 1995-11-29 Mochida Pharmaceutical Co., Ltd. Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
CA2234066C (en) 1995-10-06 2005-12-13 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
IL132318A0 (en) 1997-04-24 2001-03-19 Ortho Mcneil Pharm Inc Substituted imidazoles useful in the treatment of inflammatory diseases
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6297239B1 (en) * 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
PL340412A1 (en) 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
EP1028953A1 (en) 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
GB9820767D0 (en) * 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
EP1157026A1 (en) 1999-02-22 2001-11-28 Boehringer Ingelheim Pharmaceuticals Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
PL350357A1 (en) 1999-03-12 2002-12-02 Boehringer Ingelheim Pharma Heterocyclic urea and related compounds useful as anti−inflammatory agents
DE60023853T2 (de) 1999-03-12 2006-05-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
AU4063600A (en) * 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
CN1310906C (zh) 1999-05-21 2007-04-18 肖斯公司 用作p38激酶抑制剂的吲哚类型的衍生物
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1235804A1 (en) 1999-11-27 2002-09-04 Dong Wha Pharmaceutical Industrial Co. Ltd. Novel 3-nitropyridine derivatives and the pharmaceutical compositions containing said derivatives
US6608058B2 (en) 2000-04-17 2003-08-19 Dong Wha Pharm. Ind. Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
WO2002042292A2 (en) 2000-11-20 2002-05-30 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
DE60210755T2 (de) 2001-03-09 2006-11-16 Pfizer Products Inc., Groton Triazolopyridine als entzündungshemmende mittel
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
WO2003032989A1 (en) 2001-10-18 2003-04-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
WO2003051847A1 (en) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
AU2003221184A1 (en) * 2002-03-29 2003-10-27 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder
AU2003278088A1 (en) * 2002-10-28 2004-05-25 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
ES2390459T3 (es) * 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
EP1883404A4 (en) * 2005-05-11 2010-03-31 Array Biopharma Inc P38 INHIBITORS AND METHODS OF USE

Also Published As

Publication number Publication date
WO2004078116A2 (en) 2004-09-16
US7521447B2 (en) 2009-04-21
CA2517517C (en) 2012-12-18
NO20054453D0 (no) 2005-09-26
CA2517517A1 (en) 2004-09-16
WO2004078116A3 (en) 2004-10-14
EP1606283A4 (en) 2007-05-23
PL214032B1 (pl) 2013-06-28
WO2004078116A9 (en) 2008-09-12
MXPA05009459A (es) 2006-05-17
KR101099281B1 (ko) 2011-12-26
PL378432A1 (pl) 2006-04-03
RU2005131197A (ru) 2006-05-10
EP1606283B1 (en) 2008-10-08
EP1606283A2 (en) 2005-12-21
NO328913B1 (no) 2010-06-14
AU2004218463B2 (en) 2009-07-16
KR20050106484A (ko) 2005-11-09
US20040192653A1 (en) 2004-09-30
RU2357957C2 (ru) 2009-06-10
NO20054453L (no) 2005-11-29
IS8037A (is) 2005-09-21
AU2004218463A1 (en) 2004-09-16
JP4617299B2 (ja) 2011-01-19
JP2006519259A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
DK1997809T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS2675B (is) P38-hindrar og aðferðir til notkunar þeirra
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
NO20040640L (no) Anordning og fremgangsmate
NO2017017I1 (no) umeklinidium og vilanterol
IS8204A (is) Tæki og aðferð til að hluta niður
NO20044915L (no) C-aryl-glukosid SGLT2 inhibitorer og metode
DK1583542T3 (da) Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
DK1499311T3 (da) Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
DK2267930T3 (da) Fremgangsmåde og indretning til retransmission
DK2305250T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
DK1715893T3 (da) Direkte kompressionsformulering og fremgangsmåde
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
DK1426784T3 (da) Indretning og fremgangsmåde til positionsbestemmelse
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1703965T3 (da) Indretning, fremgangsmåde og anvendelse til at danne små partikler
IS7572A (is) Aðferð og efni til lækninga
NO20044012D0 (no) Fremgangsmate og et system
DK1819489T3 (da) Indretning og fremgangsmåde til portionering
NO322006B2 (no) Anordning og fremgangsmåte for brønnintervenering
NO20044848D0 (no) Anordning og fremgangsmate
DK1662867T3 (da) Insekticid-forbindelser og fremgangsmåder til valg deraf
IS8489A (is) Umritunarstillar og aðferðir þeirra